Middle East & Africa In-vitro Diagnostics Market Size, Share & COVID-19 Impact Analysis, By Product Type (Instruments and Reagents & Consumables), By Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Hematology, and Others), By Setting (Laboratories and Point of Care), By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, and Others), By End-user (Clinical Laboratories, Hospitals, Physician’s Offices, and Others), and Regional Forecast, 2023-2030

The Middle East & Africa captured a significant share in the global in-vitro diagnostics market. It is projected to record a CAGR of 4.5% during the forecast period. The global market for in-vitro diagnostics is projected to grow from USD 94.67 billion in 2022 to USD 157.02 billion by 2030.

The Middle East & Africa in-vitro diagnostics market growth is derived from a growing preference for early disease diagnosis, increasing prevalence of chronic diseases, rising adoption of advanced technologies to develop cutting-edge devices, growing healthcare expenditure, and increasing interest of market players to expand their business in this emerging region.

• For instance, according to the International Trade Administration, in 2022, Saudi Arabia spent around USD 36.8 billion on healthcare and social development, which was around 14.4% of its 2022 budget and the third most significant expenditure after education and military. Also, the objective of the Saudi Arabian Government is the privatization of its healthcare sector, which further creates lucrative opportunities for the market players. These factors will positively influence the market growth during the forecast period.

The Middle East & Africa in-vitro diagnostics market report covers the following countries/regions – GCC, Saudi Arabia, and the Rest of Middle East & Africa.

LATEST TRENDS

Increasing Investments to Conduct Events and Exhibitions Will Create Awareness about IVD Products

The total healthcare expenditure by key countries in the region is growing, leading to increased participation by many international companies to expand product awareness. In February 2023, Dubai organized two grand exhibitions for the medical industry, Medlab Middle East 2023 and Arab Health 2023.

• In Medlab Middle East 2023, Mindray exhibited its Total Laboratory Solution model for large-volume laboratories, which showcased how the company’s in-vitro diagnostics products and solutions can cater to laboratories with different sample volumes. The product and service connect the company’s hematology, coagulation, biochemistry, and immunoassay analyzer to meet different testing needs.

Such initiatives by the medical device industry in the Middle East & Africa will encourage leading market players to exhibit their products, which will increase the demand for in-vitro diagnostics. This will eventually help them expand their operations in the region, thereby helping the Middle East & Africa in-vitro diagnostics market share grow.

DRIVING FACTORS

Rising Collaborations and Partnerships with International Players to Drive Market Growth

The proactive initiatives by market players are anticipated to strengthen the in-vitro diagnostics market in the Middle East & Africa. These strategic initiatives can increase business operations, balance resource management, and optimize expenses, promoting efficient processes. They will also boost trade activities among the countries, thereby contributing to the market growth at a global level.

• For instance, in July 2022, Anwa Medical Co., a Saudi Arabian genomic diagnostics laboratory group, announced that it signed a Memorandum of Understanding (MoU) with Imagia Canexia Health, a Canadian genomics-based cancer treatment testing company. The alliance was aimed at increasing health equity through Imagia Canexia Health’s distributed liquid biopsy testing products in Saudi Arabia and the rest of the Middle East and North Africa.


• Similarly, in March 2022, Audere partnered with Medical Diagnostech, a South Africa-based company that develops and manufactures lateral flow rapid diagnostic test kits. The partnership aimed to integrate these companies’ products, the MD SARS-CoV-2 antigen device, with the HealthPulse digital companion app developed by Audere.

Moreover, the continuously increasing diabetes cases in the region will further propel the market growth.

RESTRAINING FACTORS

Lack of Awareness of Reimbursement Schemes to Limit Market Growth 

The complex regulatory environment in the Middle East & Africa can make the reimbursement of in-vitro diagnostics devices challenging. Also, the region’s healthcare facilities are not equipped with capital-intensive devices, limiting the usage and adoption of technologically advanced products.

• For instance, according to a report published by the Southern African Research & Innovation Management Association, the medical device industry in South Africa is small, and neither the patient nor clinician knows the device's cost. There are no incentives as well that can minimize the cost of the device. Thus, lack of awareness about reimbursement schemes is anticipated to limit the market growth.

KEY INDUSTRY PLAYERS

In terms of competitive landscape, F. Hoffmann-La Roche Ltd., Abbott, and Danaher Corporation are the key players in the Middle East & Africa market. This is attributed to the companies’ strong product offerings, active involvement in R&D investments to accelerate the product launches and approvals.

Other prominent players, such as Becton Dickinson and Company, Bio-Rad Laboratories, and BioMerieux SA are also leading the market due to their strong distribution network and diverse product portfolios. These companies are focused on strengthening their product ranges and distribution networks through strategic collaborations and partnerships to increase their share in the Middle East & Africa market.

LIST OF KEY COMPANIES PROFILED:

• bioMérieux SA (France)


• Qiagen N.V. (Germany)


• F. Hoffmann-La Roche Ltd (Switzerland)


• Siemens Healthineers AG (Germany)


• DiaSorin S.p.A. (Italy)


• Danaher Corporation (U.S.)


• Bio-Rad Laboratories (U.S.)


• Abbott (U.S.)


• Becton Dickinson and Company (U.S.)


• Quidel Corporation (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• December 2022: F. Hoffmann-La Roche Ltd. announced that it secured the ISO27001 Information Security certification in recognition of its commitment to protecting critical patient data and building trust across the region. It’s the first company in the Middle East & Africa to achieve this prestigious certification.


• September 2022: Nanōmix Corporation announced that it entered into a distribution agreement with IPS Genomix s.a.l., a medical diagnostics distributor in the Middle East. Under the distribution agreement, IPS would market and distribute the Nanōmix eLab system, including the Nanōmix S1 Panel assay and other new test products in the future for the eLab system, in multiple countries throughout the Middle East.


• June 2021: Aster DM Healthcare signed an MoU with F. Hoffmann-La Roche Ltd. to transform its diagnostic solutions across hospitals, clinics, and laboratories. The agreement focused on Aster’s entities in the UAE, Saudi Arabia, Qatar, and Oman.

REPORT COVERAGE

The market research report provides qualitative and quantitative insights on the market and a detailed analysis of the region’s market size & growth rate for all possible segments in the market. Along with the industry forecast, the report offers an elaborative analysis of the market’s competitive landscape and dynamics. Various key insights presented in the report are an overview of the number of tests, price analysis of types of products, regulatory scenario in key countries, pipeline analysis, new product launches, key industry developments – mergers, acquisitions & partnerships, and the impact of COVID-19 on the market.

Report Scope & Segmentation